137 related articles for article (PubMed ID: 37821543)
1. Elevated serum thyroid stimulating immunoglobulin linked to failure of first-line intravenous methylprednisolone monotherapy in moderate-to-severe thyroid eye disease.
Zloto O; Rosset A; Priel A; Landau-Prat D; Cukierman-Yaffe T; Shavit R; Agmon-Levin N; Ben Simon GJ; Sagiv O
Eye (Lond); 2024 Mar; 38(4):687-690. PubMed ID: 37821543
[TBL] [Abstract][Full Text] [Related]
2. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.
Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA
Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
[No Abstract] [Full Text] [Related]
4. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
Park J; Kim J; Kim SS; Choi HY
Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
[TBL] [Abstract][Full Text] [Related]
5. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
7. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of Thyroid-stimulating immunoglobulin in Recent Onset Symptomatic Thyroid Eye Disease.
Lai KKH; Aljufairi FMAA; Sebastian JU; Wei Y; Jia R; Chan KKW; Au EYL; Lee ACH; Ng CM; Yuen HKL; Yip WWK; Young AL; Cheng GPM; Tham CCY; Pang CP; Chong KKL
Eur Thyroid J; 2024 Jun; ():. PubMed ID: 38847819
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with the efficacy of intravenous methylprednisolone in moderate-to-severe and active thyroid-associated ophthalmopathy: A single-centre retrospective study.
Hu S; Wang Y; He M; Zhang M; Ding X; Shi B
Clin Endocrinol (Oxf); 2019 Jan; 90(1):175-183. PubMed ID: 30229982
[TBL] [Abstract][Full Text] [Related]
10. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
11. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
[TBL] [Abstract][Full Text] [Related]
12. One-year recurrence rate of Graves ophthalmopathy presenting as diplopia in the primary position after varied doses of intravenous methylprednisolone followed by oral prednisolone with dosing based on the magnetic resonance imaging findings.
Ueki S; Hasegawa Y; Hatase T; Kiyokawa M; Fukuchi T
Jpn J Ophthalmol; 2023 Jan; 67(1):91-96. PubMed ID: 36301447
[TBL] [Abstract][Full Text] [Related]
13. Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease.
Jang JH; Park JW; Park KA; Kim YD; Woo KI
Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2375-2382. PubMed ID: 36808229
[TBL] [Abstract][Full Text] [Related]
14. Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease.
Quah Qin Xian N; Alnahrawy A; Akshikar R; Lee V
Clin Ophthalmol; 2021; 15():1921-1932. PubMed ID: 34007144
[TBL] [Abstract][Full Text] [Related]
15. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C
JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308
[TBL] [Abstract][Full Text] [Related]
16. Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy.
Liu X; Wang S; Qin L; Qiang W; Dahal M; Fan P; Gao S; Shi B
Exp Ther Med; 2016 Aug; 12(2):901-908. PubMed ID: 27446294
[TBL] [Abstract][Full Text] [Related]
17. Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?
Liu P; Luo B; Chen L; Wang QX; Yuan G; Jiang GH; Zhang J
Front Endocrinol (Lausanne); 2021; 12():614536. PubMed ID: 33716970
[TBL] [Abstract][Full Text] [Related]
18. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Cavaletti G; Giannini F; Sabatelli M; Beghi E;
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):729-34. PubMed ID: 25246645
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease.
Ko J; Kook KH; Yoon JS; Woo KI; Yang JW;
BMJ Open; 2022 Jun; 12(6):e050337. PubMed ID: 35728893
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.
Zhang KY; Duan WW; Luo YB; Li Y; Hu J; Yang H
Orphanet J Rare Dis; 2024 Jan; 19(1):19. PubMed ID: 38243274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
